Ipsen SA (ADR: IPSEY) generates a steady flow of news centered on its activities as a global, mid-sized biopharmaceutical company focused on Oncology, Rare Disease and Neuroscience. This news page aggregates company announcements, partner releases and regulatory updates that mention Ipsen and its ADR program, giving readers a focused view of developments that can influence perceptions of IPSEY.
Recent news highlights Ipsen’s role in advancing specialty care medicines. In oncology, the company has reported Phase III NAPOLI 3 trial results for an investigational Onivyde-based regimen (NALIRIFOX) in previously untreated metastatic pancreatic ductal adenocarcinoma, with statistically significant improvements in overall and progression-free survival compared to a nab-paclitaxel plus gemcitabine regimen. Ipsen has also nominated a first clinical drug candidate from its multi-year oncology collaboration with Marengo Therapeutics, based on Marengo’s STAR T cell activator platform for solid tumors.
In rare diseases, news items cover Ipsen’s work in pediatric cholestatic liver diseases and ultra-rare conditions. Examples include Health Canada’s approval of Bylvay (odevixibat) for pruritus due to Progressive Familial Intrahepatic Cholestasis, under a partnership with Medison Pharma, and regulatory interactions for palovarotene in fibrodysplasia ossificans progressiva, including a CHMP negative opinion and a U.S. FDA Complete Response Letter. Corporate news also details Ipsen’s agreement to acquire Albireo, adding Bylvay and other bile acid modulators to its rare disease portfolio.
Neuroscience and rare neurological disease updates feature Ipsen’s collaboration with Skyhawk Therapeutics to discover RNA-targeting small molecules for rare neurological diseases. Partner announcements describe Ipsen’s option to obtain exclusive global rights to development candidates and its responsibility for later-stage development and commercialization.
Investors and observers can use this news feed to follow Ipsen’s clinical trial readouts, regulatory decisions, licensing deals, acquisitions and capital markets disclosures that reference IPSEY. Regularly reviewing these updates can help contextualize the company’s therapeutic focus and strategic direction as reflected in public announcements.
Ipsen (ADR: IPSEY) announced the completion of its acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company. The deal adds navtemadlin, an oral MDM2 inhibitor in Phase III development for myelofibrosis patients who have a suboptimal response to standard first-line therapy ruxolitinib.
The Phase III POIESIS trial is evaluating whether adding navtemadlin to ruxolitinib can improve clinical outcomes versus ruxolitinib alone in intermediate- and high-risk TP53wt myelofibrosis. According to Ipsen, early data suggest the potential to convert suboptimal responses into clinically meaningful responses and possibly provide disease-modifying benefit, subject to successful trials and regulatory approvals.
Ipsen (OTC: IPSEY) published its monthly regulatory disclosure on the share capital and voting rights for Euronext Paris as of 31 July 2026. The company reported 83,814,526 shares outstanding, a gross total of 132,132,996 voting rights and a net total of 130,919,315 voting rights.
Ipsen (OTC:IPSEY) reported weekly activity under its share buy-back programme for 11 August 2026, in line with Article 5 of MAR. The company repurchased a total of 10,000 shares of instrument FR0010259150 across four markets, at a total daily weighted average purchase price of 156.0144 per share.
Ipsen (OTC:IPSEY) reported weekly share repurchases under its buy-back programme for 4–5 August 2026 in accordance with Article 5 of MAR. The company bought back a total of 17,818 shares of ISIN FR0010259150 at a weighted average price of €157.3881 across XPAR, AQEU, TQEX and CEUX.
Ipsen (OTC: IPSEY) reported details of its share buy-back programme for 27–31 July 2026 under Article 5 of MAR. Over this week, Ipsen repurchased 12,313 shares of its stock (ISIN FR0010259150) on the XPAR market at a weighted average price of €159.9296 per share.
Ipsen (ADR: IPSEY) reported strong H1 2026 results, with total sales of €2,190.2m, up 20.4% as reported and 23.5% at constant exchange rates, and portfolio-beyond-Somatuline sales growing 24.8% at CER. Core operating income rose 28.8% to €844.9m, lifting the core operating margin to 38.6%, up 2.5 points. IFRS net profit increased 20.0% to €402.6m, and free cash flow rose 34.9% to €651.7m, taking closing net cash to €1,004.9m.
On this basis, Ipsen upgraded its 2026 guidance to total sales growth >20% at constant currency (from >13%) and a core operating margin >37% (from >35%), while absorbing higher R&D and the dilutive impact of the Memo Therapeutics and Kartos Therapeutics acquisitions.
The company highlighted multiple pipeline advances, including positive Phase III results for Dysport in episodic and chronic migraine and for Iqirvo in primary biliary cholangitis, alongside the acquisition of Memo Therapeutics (potravitug) and an agreement to acquire Kartos Therapeutics (navtemadlin). Ipsen also reported that the Phase III BOLD trial of Bylvay in biliary atresia did not meet its primary endpoint.
Ipsen (ADR: IPSEY) announced the co-optation of Catherine Bradley, CBE, as an independent Director to its Board of Directors, effective immediately, replacing Ms. Witts, who stepped down following the 13 May 2026 Annual General Meeting.
According to Ipsen, Ms. Bradley brings over three decades of investment banking and international financial markets experience and more than ten years as a non-executive director. She has held senior roles at Merrill Lynch, Crédit Suisse and BNP Paribas, and has chaired audit committees at the UK FCA, Aberdeen, Groupe Peugeot and Worldpay.
The Board has appointed her Chair of the Audit Committee and a member of the Compensation Committee. Her mandate will be submitted for ratification at the next Annual Shareholders’ Meeting and, if approved, will run until the 2029 Annual Shareholders’ Meeting, completing Ms. Witts’ term. Ipsen’s Board remains composed of 14 directors, equally split between seven women and seven men, including four independent directors and two employee representatives.
Ipsen (OTC: IPSEY) reported weekly share buybacks under its Art 5 MAR programme for the period 20–24 July 2026. The company repurchased a total of 13,930 shares of instrument FR0010259150 across XPAR, CEUX and AQEU, at an overall weighted average price of 159.2669.